All Updates

All Updates

icon
Filter
Funding
Insitro raises USD 400 million in Series C funding
AI Drug Discovery
Mar 15, 2021
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Mar 15, 2021

Insitro raises USD 400 million in Series C funding

Funding

  • Insitro, a California-based AI drug discovery and development company, has raised USD 400 million in Series C funding. The round was led by Canada Pension Plan Investment Board (CPP Investments), with participation from existing investors Andreessen Horowitz, T. Rowe Price Associates, GV, BlackRock, and new investors Temasek and Softbank Investment Advisors, among others. 

  • The round brings the company’s total funds raised to USD 743 million, making it one of the highest-funded startups in the AI drug discovery space. 

  • The company plans to use the proceeds to further develop its AI platform’s capabilities and advance its drug pipeline.  

  • Founded in 2018, Insitro’s drug discovery approach is based on test tube experiments involving cells outside the human body to predict what drug developers would see in a human clinical model. Using this method, it creates models of genetic diseases and applies AI to find differences between healthy and sick cells. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.